Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$71.38
+0.2%
$71.56
$29.18
$117.33
$7.55B0.191.14 million shs1.74 million shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.86
-1.8%
$4.20
$2.64
$5.92
$3.13B0.7948,075 shs2,996 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.45
+0.1%
$10.97
$8.73
$13.06
$7.78B1.165.68 million shs18.14 million shs
Viatris Inc. stock logo
VTRS
Viatris
$8.87
+1.1%
$8.49
$6.85
$13.55
$10.29B0.911.00 million shs18.66 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
0.00%+0.08%-6.53%+21.45%+153.07%
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00%+0.71%+9.65%+36.60%-5.88%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%-0.26%+3.62%+6.02%+5.54%
Viatris Inc. stock logo
VTRS
Viatris
0.00%-3.52%-1.24%-4.15%-12.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.6659 of 5 stars
3.51.00.04.23.44.21.9
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.2619 of 5 stars
3.53.00.00.01.42.50.0
Viatris Inc. stock logo
VTRS
Viatris
2.4807 of 5 stars
1.94.02.50.01.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2593.68% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00
N/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5052.84% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.80
Reduce$10.4017.25% Upside

Current Analyst Ratings Breakdown

Latest HYPMY, VTRS, ROIV, and CORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/6/2025
Viatris Inc. stock logo
VTRS
Viatris
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$10.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
4/21/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
4/3/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.00
4/1/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $142.00
3/31/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$76.00 ➝ $150.00
3/31/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$115.00 ➝ $150.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M11.21$1.24 per share57.36$6.49 per share11.00
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.23$0.46 per share10.47$3.54 per share1.37
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M267.95N/AN/A$7.45 per share1.54
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.71$5.16 per share1.72$15.61 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1661.5338.58N/A19.33%20.40%16.64%8/4/2025 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2420.23N/A12.51%6.95%3.34%7/23/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
-$634.20M-$3.17N/A3.45N/A-26.45%16.20%7.01%8/7/2025 (Estimated)

Latest HYPMY, VTRS, ROIV, and CORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.49$0.50+$0.01-$2.55$3.30 billion$3.25 billion
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
3/20/2025Q4 2024
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A$0.02N/A$0.02N/A$258.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.112.27%N/A45.83%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
$0.485.41%N/AN/A N/A

Latest HYPMY, VTRS, ROIV, and CORT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.55%5/23/20255/23/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47
Viatris Inc. stock logo
VTRS
Viatris
1.02
1.68
0.97

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.80%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million83.99 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable
Viatris Inc. stock logo
VTRS
Viatris
32,0001.17 billion1.17 billionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$71.38 +0.14 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$71.16 -0.22 (-0.31%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$4.86 -0.09 (-1.82%)
As of 02:34 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.45 +0.01 (+0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$11.64 +0.20 (+1.70%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Viatris stock logo

Viatris NASDAQ:VTRS

$8.87 +0.10 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$8.82 -0.05 (-0.62%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.